GLOW — Zolbetuximab Plus CAPOX in Claudin-18.2-Positive, HER2-Negative Advanced Gastric or GEJ Adenocarcinoma (GLOW)

Phase 3 · 2023 · Gastric Cancer, Gastroesophageal Junction Cancer

Design

Randomized double-blind trial of zolbetuximab plus CAPOX versus placebo plus CAPOX.

Population

Untreated claudin-18.2-positive, HER2-negative locally advanced or metastatic gastric or GEJ adenocarcinoma.

Primary Endpoint

progression-free survival (PFS)

Key Result

PFS 8.2 vs 6.8 months (HR 0.69) and overall survival 14.4 vs 12.2 months (HR 0.77), confirming the SPOTLIGHT result with a CAPOX backbone.

Guideline Impact

NCCN-listed zolbetuximab plus CAPOX for first-line CLDN18.2-positive, HER2-negative gastric/GEJ adenocarcinoma